melanoma

ances. As research advances, the development of melanoma-specific tracers and hybrid imaging techniques promises to further refine disease detection and guide personalized therapy. For clinicians, staying informed about these innovations and applying best practices will improve patient outcome

as: Anti-CTLA-4 agents (e.g., ipilimumab) Anti-PD-1 agents (e.g., pembrolizumab, nivolumab) Targeted Therapy: For BRAF-mutant melanomas, BRAF inhibitors (e.g., vemurafenib, dabrafenib) combined with MEK inhibitors (e.g.,

rregular contours. Nuclear to cytoplasmic ratio: Increased, with prominent nucleoli. Mitotic activity: Increased, including atypical mitoses, especially in the dermal component. Pagetoid spread: Presence of atypical melanocytes above the basal layer,